NBY vs PG

For growth investors, The Procter & Gamble Company (PG) is the stronger pick with 0.

3% revenue growth year-over-year, versus -6. 4% for NovaBay Pharmaceuticals, Inc. (NBY). The Procter & Gamble Company (PG) offers the better valuation at 22. 7x trailing P/E (21. 4x forward), making it the more compelling value choice. Analysts rate The Procter & Gamble Company (PG) a "Buy" — based on 52 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, The Procter & Gamble Company (PG) delivered a total return of +23.

8%, compared to -99. 9% for NovaBay Pharmaceuticals, Inc. (NBY). Over 10 years, the gap is even starker: PG returned +121. 5% versus NBY's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Procter & Gamble Company (PG) is the lower-risk stock at 0.

10β versus NovaBay Pharmaceuticals, Inc. 's 2. 43β — meaning NBY is approximately 2244% more volatile than PG relative to the S&P 500.

By revenue growth (latest reported year), The Procter & Gamble Company (PG) is pulling ahead at 0.

3% versus -6. 4% for NovaBay Pharmaceuticals, Inc. (NBY). On earnings-per-share growth, the picture is similar: NovaBay Pharmaceuticals, Inc. grew EPS 98. 2% year-over-year, compared to 8. 1% for The Procter & Gamble Company. Over a 3-year CAGR, PG leads at 1. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

The Procter & Gamble Company (PG) is the more profitable company, earning 19.

0% net margin versus -73. 8% for NovaBay Pharmaceuticals, Inc. — meaning it keeps 19. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PG leads at 24. 3% versus -59. 7% for NBY. At the gross margin level — before operating expenses — NBY leads at 66. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, PG (2.

7% yield) pays a dividend. NBY does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, The Procter & Gamble Company (PG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

10), 2. 7% yield, +121. 5% 10Y return). NovaBay Pharmaceuticals, Inc. (NBY) carries a higher beta of 2. 43 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PG: +121. 5%, NBY: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NBY (Healthcare) and PG (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

PG pays a dividend while NBY does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.